Arcutis Biotherapeutics, Inc. ARQT Business Segments — Operating Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s business segments — operating income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s business segments — operating income (loss)?
- Arcutis Biotherapeutics, Inc. (ARQT) reported business segments — operating income (loss) of -$9.09M in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s business segments — operating income (loss) changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s business segments — operating income (loss) increased by 62.9% year-over-year, from -$24.53M to -$9.09M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s business segments — operating income (loss)?
- Over 2 years (2022 to 2024), Arcutis Biotherapeutics, Inc.'s business segments — operating income (loss) has grown at a -34.8% compound annual growth rate (CAGR), from -$301.63M to -$128.4M.
- What does business segments — operating income (loss) mean?
- Measures the profitability of the reportable segment by subtracting total operating expenses from total revenues. It serves as a key indicator of the segment's ability to generate sustainable returns from its core commercial and development activities.